The Company was set up by the Founding Directors in August 2020 as a Special Purpose Acquisition Company (SPAC), to pursue opportunities to acquire medical biotechnology businesses that are early stage, in order to provide Shareholders with an attractive total return achieved primarily through capital appreciation, by investing in the medical sector to include, but not limited to:
- Drug and vaccine development;
- Immuno-therapy; and
- Cell and gene therapies
The Company considers medical biotechnology businesses that are in the “research’ or “pre-clinical
development” stages to be early stage.
Admission to Trading on the Official List
On 22nd March 2021, dealings commenced by way of a Placing of 20,000,000 Placing Shares at a Placing Price of 5 pence each and Admission to the Official List of 32,400,000 Ordinary Shares of nominal value 1 penny each.
The Perivan shareholder communications team were delighted to work with Optiva Securities who were appointed Placing Agent and Adviser, and Locke Lord who were appointed Solicitors to Roquefort Investments on the successful publication of the 84-page prospectus.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed-ended funds.